Product category:
Contract research
News Release from: Nanostream | Subject: LD System
Edited by the Laboratorytalk Editorial
Team on 27 July 2007
Outsourcing of assay development speeds
discovery
By employing a separation-based approach, Nanostream says it has the capability to develop a variety of challenging assays including kinase assays, lipid-modifying enzyme assays and protease assays
Nanostream, a provider of products and services to increase productivity in laboratories at pharmaceutical and biotech companies, launches a new services organisation to deliver assay development services and customised solutions for screening labs Nanostream is entering the drug discovery services market based on the growing need for pharmaceutical and biotech companies to outsource costly aspects of the drug discovery process, including assay development, optimization and qualification
This article was originally published on Laboratorytalk on 4 Oct 2006 at 8.00am (UK)
Related stories
Simple and flexible hit to lead identification
Nanostream will host a webinar on 'A simple and flexible system for hit to lead identification' on Wednesday, October 4 at 11:00am EST
Breadth of biological assays demonstrated at SBS
Nanostream says its scientists continue to pioneer assay data for a range of biological assays performed using the Nanostream LD system, an automated assay detection platform
By employing a separation-based approach to developing assays, Nanostream has the capability to develop a variety of challenging assays including kinase assays, lipid-modifying enzyme assays and protease assays.
The company's technology, the Nanostream LD System, serves as a single platform for assays throughout the entire screening process - from target characterisation through lead optimisation.
This platform affords direct measurement of enzyme activity and rapid IC50 determination.
Further reading
Micro parallel liquid chromatography system shown
Unveiled at LabAutomation 2004, this mPLC system increases sample analysis capacity by enabling 24 simultaneous separations
Increased sensitivity and selectivity
Addition of fluorescence detection to micro parallel liquid chromatography system increases sensitivity and selectivity and enables detection for separation-based assays
Second-generation 24-column HPLC cartridges
Cartridges with shorter columns enable faster LC separations for greater throughput; longer use cartridges allow analysis of more samples using a single device
"The pharmaceutical industry continues to explore ways to reduce costs and conserve resources, so there is a growing trend for scientists to outsource drug discovery processes.
"Assay development is a critical area that is typically time and labor intensive with traditional methods often yielding ambiguous results, " said Stephen O'Connor, CEO, Nanostream.
"With our separation-based assay detection platform, we can develop our customers' most difficult assays and deliver unmatched qualitative and quantitative data results in a rapid timeframe".
Jonas Ekblom brings an extensive background in pharmacology and drug discovery including over 15 years of combined academia and industry experience to his role as chief operating officer at Nanostream.
He has a strong track record in strategic R+D management and leading cross-functional expert teams.
As COO, he will spearhead Nanostream's entry into the drug discovery services market and oversee management of the organisation.
"Jonas has a wealth of knowledge in biochemical assays and proven success in helping customers improve efficiencies and adopt new technologies to speed drug discovery, " continued O'Connor.
"We are excited to have him join our management team and drive our assay development services.
"Under his leadership, I am confident that his team will provide exceptional, highly customised services to our growing customer base." Ekblom joins the company from Invitrogen, where he was head of the global programme and portfolio management group.
Prior to his role at Invitrogen, he served as director of drug discovery at Sequenom.
Ekblom has held senior management positions at Pharmacia, and was a cofounder of Biovitrum in 2000 and Anaborex in 2004.
At Biovitrum, he was responsible for the corporate in vitro pharmacology function and was responsible for the build-up of the company's HTS facility.
Ekblom has published more than 50 articles and holds a position as associate professor in pharmacology at Uppsala University in Sweden.
He received a BS from the University of Stockholm and a PhD in experimental neurology at Uppsala University.
• Nanostream: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
